TPI obtains GMP certification for Qionglai Tianyin Facility

Jan 20 2015NewsGuard 100/100 Score

Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the TPI's Qionglai Tianyin Facility (QLF) has received its Good Manufacturing Practice (GMP) certificate from the China Food & Drug Administration's (CFDA) with the GMP certification processing number: SC20140067. The latest GMP certification has improved significantly regarding the level of stringency, standardization, quality control and etc and the receipt of the new GMP status is regarded a prominent advantage for the future growth of a pharmaceutical enterprise.

The GMP certification of QLF provides the basis for the growth platform of the strategic Alliance between TPI and Buchang Pharmaceutical Co., Ltd. ("Buchang Pharma", www.buchang.com and its Shanghai main board pre-IPO prospectus: http://www.csrc.gov.cn/pub/zjhpublic/G00306202/201406/t20140620_256436.htm) focusing on TPI's lead revenue driver Gingko Mihuan Oral Liquid (GMOL).

SOURCE Tianyin Pharmaceutical Co., Inc.

Posted in: Business / Finance

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing
Expanded access to weight-loss drugs could save thousands of lives
Expanding access to GLP-1 weight-loss drugs could save thousands of lives
Study shows large language models susceptible to misinformation
Exploring Japanese medicine: Longevity, lifestyle, and emerging health priorities
Diabetes drugs may reduce risk of opioid overdose and alcohol intoxication
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation
Unlocking the secrets of analytical services: An insider interview with colman byrne

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)